Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial
SM Opal, PF Laterre, B Francois, SP LaRosa… - Jama, 2013 - jamanetwork.com
Importance Eritoran is a synthetic lipid A antagonist that blocks lipopolysaccharide (LPS)
from binding at the cell surface MD2-TLR4 receptor. LPS is a major component of the outer
membrane of gram-negative bacteria and is a potent activator of the acute inflammatory
response. Objective To determine if eritoran, a TLR4 antagonist, would significantly reduce
sepsis-induced mortality. Design, Setting, and Participants We performed a randomized,
double-blind, placebo-controlled, multinational phase 3 trial in 197 intensive care units …
from binding at the cell surface MD2-TLR4 receptor. LPS is a major component of the outer
membrane of gram-negative bacteria and is a potent activator of the acute inflammatory
response. Objective To determine if eritoran, a TLR4 antagonist, would significantly reduce
sepsis-induced mortality. Design, Setting, and Participants We performed a randomized,
double-blind, placebo-controlled, multinational phase 3 trial in 197 intensive care units …